Last week’s significant news was dominated by licensing deals and mergers and acquisitions. US biotech giant Biogen entered ...

Like other developers of recently approved gene therapies, Bluebird has been slow to generate demand for its products. That reflects challenges in securing reimbursement from payers stemming from ...